MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

Search

Boston Scientific Corp.

Atidarymo kaina

SektoriusSveikatos priežiūra

101.38 0.83

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

100.42

Max

101.95

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-138M

562M

Pardavimai

352M

4.6B

P/E

Sektoriaus vid.

74.864

57.333

Pelnas, tenkantis vienai akcijai

0.7

Pelno marža

12.322

Darbuotojai

53,000

EBITDA

-41M

1B

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+18.99% upside

Dividendai

By Dow Jones

Kitas uždarbis

2025-07-23

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-14B

138B

Ankstesnė atidarymo kaina

100.55

Ankstesnė uždarymo kaina

101.38

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Strong Bullish Evidence

Boston Scientific Corp. Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-04-23 12:16; UTC

Uždarbis
Pagrindinės rinkos jėgos

Boston Scientific Shares Higher on Rosy Outlook, 1Q Beats

2025-03-03 12:35; UTC

Įsigijimai, susijungimai, perėmimai

Boston Scientific to Buy Rest of SoniVie for Initial $360 Million

2025-02-05 12:23; UTC

Uždarbis

Boston Scientific 4Q Profit Up on Strong Cardio Device Sales

2025-04-23 10:32; UTC

Uždarbis

Boston Scientific Sees 2Q Reported Sales Up 17.5%-19.5%, Organic Sales Up 13%-15% >BSX

2025-04-23 10:31; UTC

Uždarbis

Boston Scientific Sees 2025 Reported Sales Up 15%-17%, Organic Sales Up 12%-14% >BSX

2025-04-23 10:30; UTC

Uždarbis

Boston Scientific 1Q EPS 45c >BSX

2025-04-23 10:30; UTC

Uždarbis

Boston Scientific 1Q Adj EPS 75c >BSX

2025-04-23 10:30; UTC

Uždarbis

Boston Scientific Sees FY Adj EPS $2.87-Adj EPS $2.94 >BSX

2025-04-23 10:30; UTC

Uždarbis

Boston Scientific 1Q Sales $4.66B >BSX

2025-04-23 10:30; UTC

Uždarbis

Boston Scientific Sees 2Q Adj EPS 71c-Adj EPS 73c >BSX

2025-04-23 10:30; UTC

Uždarbis

Boston Scientific Sees 2Q EPS 45c-EPS 47c >BSX

2025-04-23 10:30; UTC

Uždarbis

Boston Scientific 1Q Organic Sales Up 18.2% >BSX

2025-04-23 10:30; UTC

Uždarbis

Boston Scientific Sees FY EPS $1.86-EPS $1.93 >BSX

2025-03-03 11:59; UTC

Įsigijimai, susijungimai, perėmimai

Boston Scientific to Pay Up to Additional $180 Million Upon Achievement of Regulatory Milestone >BSX

2025-03-03 11:58; UTC

Įsigijimai, susijungimai, perėmimai

Boston Scientific to Buy Rest of SoniVie for Initial $360 Million >BSX

2025-03-03 11:58; UTC

Įsigijimai, susijungimai, perėmimai

Boston Scientific Announces Agreement To Acquire SoniVie Ltd. >BSX

2025-02-05 21:33; UTC

Uždarbis

How Boston Sci Leaned On Its New Heart Device For A Fourth-Quarter Beat -- IBD

2025-02-05 15:20; UTC

Uždarbis

How Boston Sci Leaned On Its New Heart Device For A Fourth-Quarter Beat -- IBD

2025-02-05 11:39; UTC

Uždarbis

Boston Scientific Sees 1Q Organic Sales Up 14%-16% >BSX

2025-02-05 11:39; UTC

Uždarbis

Boston Scientific Sees 1Q Sales Up 17%-19% >BSX

2025-02-05 11:38; UTC

Uždarbis

Boston Scientific Sees 2025 Organic Sales Up 10%-12% >BSX

2025-02-05 11:38; UTC

Uždarbis

Boston Scientific Sees 2025 Sales Up 12.5%-14.5% >BSX

2025-02-05 11:37; UTC

Uždarbis

Boston Scientific 4Q Organic Sales Up 19.5% >BSX

2025-02-05 11:37; UTC

Uždarbis

Boston Scientific 4Q Adj EPS 70c >BSX

2025-02-05 11:37; UTC

Uždarbis

Boston Scientific Sees FY EPS $1.86-EPS $1.93 >BSX

2025-02-05 11:37; UTC

Uždarbis

Boston Scientific 4Q Sales $4.56B >BSX

2025-02-05 11:37; UTC

Uždarbis

Boston Scientific Sees FY Adj EPS $2.80-Adj EPS $2.87 >BSX

2025-02-05 11:37; UTC

Uždarbis

Boston Scientific Sees 1Q Adj EPS 66c-Adj EPS 68c >BSX

2025-02-05 11:37; UTC

Uždarbis

Boston Scientific Sees 1Q EPS 43c-EPS 45c >BSX

2025-02-05 11:37; UTC

Uždarbis

Boston Scientific 4Q EPS 38c >BSX

Akcijų palyginimas

Kainos pokytis

Boston Scientific Corp. Prognozė

Kainos tikslas

By TipRanks

18.99% į viršų

12 mėnesių prognozė

Vidutinis 120.35 USD  18.99%

Aukščiausias 135 USD

Žemiausias 110 USD

Remiantis 23 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Boston Scientific Corp. kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

23 ratings

22

Pirkti

1

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

95.25 / 102.37Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Strong Bullish Evidence

Vidutinės trukmės periodas

Strong Bearish Evidence

Ilgalaikis periodas

No Evidence

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Boston Scientific Corp.

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system. It also provides technologies for diagnosing and treating coronary artery disease and aortic valve conditions; WATCHMAN FLX, a Left Atrial Appendage Closure Device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, quadripolar LV leads, ICD leads, pacing leads, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, the company offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose, treat and ease forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.